Skip to main content
Full access
Ask the Expert
Published Online: 14 July 2023

Treating Motivational and Consummatory Aspects of Anhedonia

How does anhedonia manifest across psychiatric disorders, including posttraumatic stress disorder? What factors guide treatment selection for anhedonic symptoms?
Anhedonia is a devastating psychiatric symptom that is found across a variety of psychiatric disorders (1). Commonly defined as a loss of motivation, interest, or capacity to derive pleasure from previously enjoyed activities, anhedonia is one of the rare transdiagnostic symptoms that spans the internalizing, externalizing, and thought-disorder dimensions of the hierarchical structure underlying psychiatric disorders (25). Despite its prevalence, treatments for anhedonia have lagged behind other areas, and the development of tools for addressing anhedonia represents an area of urgent clinical need.

Varieties of Anhedonic Presentation

Growing evidence has suggested that anhedonia is a multifaceted symptom domain, and that various components of anhedonia and other symptoms may interact to drive clinical presentation. In recent decades, a consensus has emerged to separate loss of interest or motivation (i.e., motivational anhedonia) from the capacity to enjoy rewards (i.e., consummatory anhedonia) (6). Importantly, these dimensions are neither independent nor mutually exclusive. Indeed, repeated failure to derive pleasure from previously enjoyed activities can easily blunt subsequent motivation, and a loss of motivation can lead to an increase in reporting of low enjoyment, because individuals will often conclude that their lack of interest is likely due to a low expectation of reward (7).
In individuals experiencing posttraumatic stress disorder (PTSD), both motivational and consummatory aspects of anhedonia may occur (8, 9). In the aftermath of trauma, motivational and consummatory anhedonia may be closely related to—and difficult to distinguish from—behavioral avoidance and emotional numbing, respectively (9, 10). Ultimately, lower level, more specific analysis may be required to truly distinguish the varieties of anhedonia experienced in PTSD. Indeed, the division between motivational and consummatory aspects of reward has long been observed in preclinical studies, in which substantial evidence has accumulated to suggest that these processes are neurobiologically dissociable through manipulations of the mesolimbic dopamine and mu-opioid systems, respectively (11, 12). Recently, human functional MRI research (13) has also suggested that neural population coding of motivational and pleasurable aspects of reward are similarly distinct and appear to reflect a dichotomy similar to that between dopaminergic and opioidergic circuitry. Application of this research to clinical populations, however, remains in the early stages.

Treatment Hierarchies for Anhedonic Presentation

Treatment of Underlying Primary Issues

In addition to subtypes of anhedonia presentation, the widespread prevalence of anhedonia suggests that, in many cases, it is likely a consequence of other psychiatric symptoms and syndromes (i.e., “secondary anhedonia”), rather than a primary pathology in its own right. Examples of secondary anhedonia can include the low levels of enjoyment and interest reported during early stages of sobriety; a high propensity toward dissociative states that limit capacity for pleasure; and cognitive impairments that may impede the necessary planning and coordination for engaging in social activities. Pervasive anxiety resulting in limited activities and social isolation can also lead to reported loss of enjoyment. Such etiologic considerations are important for treatment customization. In some cases, secondary anhedonia may spontaneously remit if the primary issues are addressed.

Empirically Supported Behavioral Interventions for Anhedonia

Although treatment options for anhedonia have lagged behind those for other dimensions of internalizing psychopathology, evidence supporting several behavioral and pharmaceutical interventions has emerged. On the behavioral side, behavioral activation (14, 15) and positive affect therapy (16, 17) have shown evidence in enhancing behavioral engagement and reducing avoidance. Both therapies are modular and primarily target aspects of motivational impairment rather than consummatory anhedonia. Indeed, to a large extent, both therapies operate on the underlying assumption that the capacity to experience pleasure is generally intact; the primary goal of treatment is therefore to facilitate greater opportunity for engaging in pleasurable activities. This goal is often accomplished by helping patients to identify activities that provide pleasure or a sense of achievement (i.e., mastery), to prioritize these activities in daily routines, and to identify and problem-solve around barriers to these activities. For consummatory anhedonia, mindfulness-based interventions designed to focus attention on savoring rewards have been developed in the context of substance use disorders (18) and may offer strategies for enhancing pleasure in other disorders as well.

Empirically Supported Pharmacologic Interventions for Anhedonia

For pharmacologic interventions, treatment using dopaminergic agents has been found to improve symptoms of low motivation and anhedonia-associated fatigue in several studies (19, 20), consistent with a wealth of preclinical and human experimental data suggesting that enhancement of dopaminergic tone may result in greater motivated behavior (2123). Stimulants carry noteworthy side effects, however, including suppressed appetite, weight loss, hypertension, cardiac arrythmias, and potential for abuse. Despite these risks, more research into the possible application of stimulants to treat the motivational aspects of anhedonia is warranted. Indeed, a recent meta-analysis (19) evaluating the use of several agents at different dosages found that psychostimulants were generally efficacious, and their use as an adjunctive agent or monotherapy represented an understudied area.
In addition to psychostimulants, some evidence supports dopamine-replacement therapy for certain presentations of anhedonia. In particular, a growing body of evidence suggests that chronic peripheral inflammation may blunt dopamine synthesis capacity, possibly contributing to symptoms of fatigue, low motivation, and psychomotor slowing (24, 25). Initial evidence (26) suggests that administration of levodopa, a dopamine precursor commonly used to treat Parkinson’s disease, may benefit patients who show low motivation and elevated inflammation. Finally, the fast-acting antidepressant ketamine has shown some initial promise in addressing multiple aspects of anhedonia, including incapacity for pleasure (27, 28).

Summary

Taken together, anhedonia is a pervasive and challenging symptom to treat. In many cases, anhedonia may be secondary to other factors, and may improve with targeting of the underlying issues. In cases of primary anhedonia, several behavioral interventions with strong empirical support exist, although they primarily focus on motivational impairments. Dopaminergic therapies may also help patients with low motivation, although more research is needed. Finally, some initial evidence suggests that ketamine may emerge as a successful intervention strategy for primary consummatory anhedonia.

References

1.
Pizzagalli DA: Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation? Am J Psychiatry 2022; 179:458–469
2.
Zald DH, Treadway MT: Reward processing, neuroeconomics, and psychopathology. Annu Rev Clin Psychol 2017; 13:471–495
3.
Vinograd M, Stout DM, Risbrough VB: Anhedonia in posttraumatic stress disorder: prevalence, phenotypes, and neural circuitry. Curr Top Behav Neurosci 2022; 58:185–199
4.
Husain M, Roiser JP: Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci 2018; 19:470–484
5.
Strauss GP, Cohen AS: A transdiagnostic review of negative symptom phenomenology and etiology. Schizophr Bull 2017; 43:712–719
6.
Treadway MT, Zald DH: Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35:537–555
7.
Cooper JA, Arulpragasam AR, Treadway MT: Anhedonia in depression: biological mechanisms and computational models. Curr Opin Behav Sci 2018; 22:128–135
8.
Liu P, Wang L, Cao C, et al: The underlying dimensions of DSM-5 posttraumatic stress disorder symptoms in an epidemiological sample of Chinese earthquake survivors. J Anxiety Disord 2014; 28:345–351
9.
Armour C, Tsai J, Durham TA, et al: Dimensional structure of DSM-5 posttraumatic stress symptoms: support for a hybrid anhedonia and externalizing behaviors model. J Psychiatr Res 2015; 61:106–113
10.
Felmingham KL, Falconer EM, Williams L, et al: Reduced amygdala and ventral striatal activity to happy faces in PTSD is associated with emotional numbing. PLoS One 2014; 9:e103653
11.
Berridge KC, Robinson TE: Parsing reward. Trends Neurosci 2003; 26:507–513
12.
Berridge KC, Kringelbach ML: Pleasure systems in the brain. Neuron 2015; 86:646–664
13.
Kragel PA, Treadway MT, Admon R, et al: A mesocorticolimbic signature of pleasure in the human brain. bioRxiv (Epub ahead of print, Nov 1, 2022). doi:
14.
Dimidjian S, Hollon SD, Dobson KS, et al: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74:658–670
15.
Dichter GS, Felder JN, Petty C, et al: The effects of psychotherapy on neural responses to rewards in major depression. Biol Psychiatry 2009; 66:886–897
16.
Craske MG, Meuret AE, Ritz T, et al: Positive affect treatment for depression and anxiety: a randomized clinical trial for a core feature of anhedonia. J Consult Clin Psychol 2019; 87:457–471
17.
Craske MG, Meuret AE, Ritz T, et al: Treatment for anhedonia: a neuroscience driven approach. Depress Anxiety 2016; 33:927–938
18.
Garland EL: Restructuring reward processing with mindfulness‐oriented recovery enhancement: novel therapeutic mechanisms to remediate hedonic dysregulation in addiction, stress, and pain. Ann N Y Acad Sci 2016; 1373:25–37
19.
McIntyre RS, Lee Y, Zhou AJ, et al: The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. J Clin Psychopharmacol 2017; 37:412–418
20.
Rizvi SJ, Geraci J, Ravindran A, et al: Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol 2014; 34:755–759
21.
Bardgett ME, Depenbrock M, Downs N, et al: Dopamine modulates effort-based decision making in rats. Behav Neurosci 2009; 123:242–251
22.
Salamone JD, Correa M: The mysterious motivational functions of mesolimbic dopamine. Neuron 2012; 76:470–485
23.
Soder HE, Cooper JA, Lopez-Gamundi P, et al: Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning. Neuropsychopharmacology 2021; 46:1078–1085
24.
Lucido MJ, Bekhbat M, Goldsmith DR, et al: Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacological implications. Pharmacol Rev 2021; 73:1084–1117
25.
Treadway MT, Cooper JA, Miller AH: Can’t or won’t? Immunometabolic constraints on dopaminergic drive. Trends Cogn Sci 2019; 23:435–448
26.
Bekhbat M, Li Z, Mehta ND, et al: Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry 2022; 27:4113–4121
27.
Delfino RS, Del-Porto JA, Surjan J, et al: Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. J Affect Disord 2021; 278:515–518
28.
Lally N, Nugent A, Luckenbaugh D, et al: Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 2014; 4:e469

Information & Authors

Information

Published In

History

Published in print: Summer 2023
Published online: 14 July 2023

Keywords

  1. Trauma- and Stressor-Related Disorders
  2. Posttraumatic Stress Disorder
  3. Psychotherapy
  4. Activities Therapy

Authors

Details

Michael T. Treadway, Ph.D. [email protected]
Departments of Psychology and Psychiatry and Behavioral Sciences, Emory University, and Winship Cancer Institute, Atlanta.

Notes

Send correspondence to Dr. Treadway ([email protected]).

Competing Interests

In the past 2 years, Dr. Treadway has served as a paid consultant to Boehringer Ingelheim. No funding from these entities was used to support the current work, and all views expressed are solely those of the author.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share